Chondrometrics software listed as medical device on INDICATE by MICRON INC (JAPAN)

Chondrometrics GmbH is pleased to announce that its MRI-based software device for articular tissue analysis has been listed on INDICATE, a platform provided by Micron, Inc. in Japan.

This listing marks an important step in making Chondrometrics’ quantitative imaging technology more visible to companies, clinical researchers, and academic groups in Japan — one of the world’s most advanced and quality-driven healthcare and clinical research markets.

About INDICATE
INDICATE is a platform developed by Micron to support the connection between innovative diagnostic and analysis technologies and potential users in clinical trials, research, and healthcare development. The name stands for “INnovative DIagnostic Capabilities Adoption To End-users”.

Through INDICATE, Micron introduces advanced technologies — including imaging-based, AI-enabled, and software-based solutions — to companies and academic researchers who are interested in using such technologies for scientific studies and clinical trials.

For Chondrometrics, being listed on INDICATE creates a valuable opportunity to present its imaging biomarker platform to stakeholders in Japan who are active in musculoskeletal research, osteoarthritis clinical development, medical imaging, and quantitative evaluation of therapeutic response.

About Micron
Micron, Inc. is a Japan-based imaging contract research organization (iCRO) with long-standing expertise in medical imaging and clinical trial support. Headquartered in Tokyo and founded in 2005, Micron has built strong capabilities in imaging biomarkers, central imaging services, and clinical development support for pharmaceutical, biotechnology, and medical device companies.

Micron’s focus on imaging makes INDICATE a particularly relevant platform for Chondrometrics. Both companies share an interest in bringing advanced imaging technologies closer to clinical research, drug development, and evidence generation.

About Chondrometrics’ technology
The Chondrometrics software device has been developed for quantitative MRI analysis of articular tissues, including cartilage morphometry and cartilage relaxometry. These measures are widely used to evaluate structural progression in osteoarthritis with high precision, and to monitor the efficacy of potential treatment effects.

Beyond cartilage, Chondrometrics’ broader mission is to provide validated imaging biomarkers for osteoarthritis research and clinical trials. This includes quantitative measures related to inflammation, bone health, and whole-joint structural pathology, with the goal of helping researchers, sponsors, and clinical experts better understand disease mechanisms and treatment effects in osteoarthritis.

A bridge to the Japanese market and regulatory environment
Japan has a strong scientific and clinical tradition in musculoskeletal disease, medical imaging, and high-quality clinical research. Being represented on INDICATE provides Chondrometrics with a focused entry point to this important market and offers Japanese stakeholders easier access to information about the company’s imaging biomarker technology.

Chondrometrics is grateful to Micron for including its technology on the INDICATE platform and for supporting the connection between innovative medical technologies and the Japanese clinical research community. The Chondrometrics software platform has received regulatory approval as a medical device in Europe as a Class IIa device under the EU MDR 2017/745, Annex IX. The product is not yet currently approved as a medical device in Japan.